# A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

> **NCT06246916** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 560 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** fianlimab
- **DRUG:** cemiplimab
- **DRUG:** relatlimab+nivolumab

## Key facts

- **NCT ID:** NCT06246916
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2027-03-22
- **Final completion:** 2033-07-10
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246916, "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06246916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*